Illumina, Inc. (ILMN)

116,69 -1,60 (-1,35 %) À la clôture : 04:00PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 10 590

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Jacob Thaysen Ph.D.	CEO & Director	796,63k	S.O.	1975
Ms. Carissa L. Rollins	Chief Information Officer	693,52k	S.O.	1970
Mr. Charles E. Dadswell Esq.	Senior VP & General Counsel	1,03M	S.O.	1959
Stephanie Campos	President	S.O.	S.O.	S.O.
Mr. Ankur Dhingra	Chief Financial Officer	S.O.	S.O.	1976
Mr. Kevin Carl Pegels	Chief of Global Operations	S.O.	S.O.	1968
Mr. Scott Ericksen	VP & Chief Accounting Officer	S.O.	S.O.	1973
Dr. Steven Barnard Ph.D.	Chief Technology Officer	S.O.	S.O.	S.O.
Ms. Sallilyn Schwartz	Vice President of Investor Relations	S.O.	S.O.	S.O.
Mr. Jakob Wedel	Chief Strategy & Corporate Development Officer and CEO Chief of Staff	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Illumina, Inc. en date du 1 avril 2024 est 10. Les scores principaux sont Audit : 9; Société : 8; Droits des actionnaires : 7; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.